Express . . . The innovative monoantitherapy of lupus reached the clinical end of Phase 2 and significantly improved skin symptoms.

▎ Yao Ming Kant content team editor yesterday, Biogen at the European rheumatology Conference (EULAR 2020), announced the company's development of monoclonal antibody therapy biib059 treatment of skin lupus erythematosus (CLE) phase II clinical data.biib059 is an all humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2 (bdca2). Br / > compared with the placebo group, the symptoms of ib059 were significantly improved.lupus erythematosus is a chronic autoimmune disease in which the immune system attacks its own tissues, leading to a variety of different symptoms.in the past 60 years, only one new biological agent, belimumab, has been approved for the treatment of lupus erythematosus.in patients with cutaneous lupus erythematosus (CLE), the immune system attacks healthy skin, usually causing rashes and skin damage, and may cause pain or itching.cle was associated with decreased quality of life and increased depression.in some chronic diseases, patients may have scars, skin atrophy and hair loss.biib059 is a humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2 (bdca2), which is currently being developed for the treatment of patients with CLE and systemic lupus erythematosus.bdca2 is the only receptor that is expressed on the plasma like dendritic cells (pDCs) of human immune cells. It can reduce the production of inflammatory cytokines including IFN-I, and plays an important regulatory role in the pathological mechanism of lupus erythematosus.a randomized, double-blind, placebo-controlled phase 2 lilac study involving 264 participants, including patients with active CLE and SLE.in the study for patients with cle, 132 patients received different doses of biib059.the results showed that patients treated with biib059 achieved a dose-dependent remission of their skin symptoms at 16 weeks using the skin lupus disease area and severity index activity (Class-A) score.the Class-A scores of 50 mg, 150 mg and 450 mg biib059 groups were 38.8% (P = 0.015), 47.9% (P & lt; 0.001) and 42.5% (P = 0.001), respectively, significantly higher than those in the placebo group (14.5%)."we are encouraged by the results of biib059 in the cutaneous lupus section of the phase 2 lupus study," said Dr. Nathalie franchimont, vice president of multiple sclerosis and Immunology development, Bojian."our goal is to provide meaningful new therapies for lupus patients with limited treatment options."References: [1] Biogen presents positive phase 2 cubaneous lupus erythematosus (CLE) data at European e-progress of Rheumatology (EULAR) 2020.if you need guidance on treatment plan, please go to a regular hospital.